We now offer Private Weight Loss Treatments

Mounjaro vs Wegovy: What the Head-to-Head Evidence Actually Shows

Two people review information on a tablet in a consultation room.
NEWS · 6 minute read
Rahul Puri
Written by Rahul PuriPharmacist, MPharm
Medically reviewed 6 November 2026
Share:
Stay informed

Get practical health advice and updates on Puri Pharmacy services straight to your inbox.

A direct trial found greater average weight reduction with tirzepatide than semaglutide at the injection doses studied. That is useful evidence, but it does not identify the best treatment for every person. A fair comparison must name the doses, population, duration and outcomes—not just display two percentages.

At a glance

Compare the treatment studied, not just the brand name. Direct trial results describe group averages at specific doses and do not predict your outcome or cover every current formulation. Discuss suitability, tolerability and follow-up with your clinician. Aide Health can support progress recording once an individual care plan is agreed.

Illustration of a pharmacist weight-management consultation
Bring your treatment history, symptoms and questions to the review.

Start with the exact comparison

Mounjaro contains tirzepatide; Wegovy contains semaglutide. The comparison in this article concerns the once-weekly injections evaluated in SURMOUNT-5. It is not a dosing guide, a recommendation to switch or a comparison of every product containing these ingredients.

A brand name can cover different strengths or formulations over time. Always ask whether a headline refers to the same treatment being discussed in your consultation. Milligram numbers are not interchangeable between different medicines.

What SURMOUNT-5 found

SURMOUNT-5, published in the New England Journal of Medicine in 2025, randomly assigned 751 adults with obesity and without type 2 diabetes to tirzepatide or semaglutide injections for 72 weeks. It was open-label and funded by Eli Lilly.

The trial used maximum tolerated tirzepatide doses of 10 or 15 mg, and semaglutide doses of 1.7 or 2.4 mg weekly. Estimated average weight reductions were 20.2% and 13.7%, respectively: a difference of 6.5 percentage points.

Digestive adverse events were the most common in both groups, mainly mild to moderate and occurring during escalation. The trial supports a difference in average weight reduction under these conditions; it does not guarantee an individual result or establish universal superiority across every health outcome.

How to read percentages without being misled

A percentage point is not the same as a percentage. Subtracting 13.7 from 20.2 gives 6.5 percentage points. A statement that one result is “6.5% better” is not an accurate description of that subtraction.

An average is not an appointment target. A reader cannot take a study average, divide it by the number of weeks and use the result as a required weekly loss. Treatment response is not a straight-line schedule.

A weight endpoint is not a complete health assessment. Ask what matters for your own care: tolerability, nutritional intake, health conditions, practical use and longer-term support. A larger average change in one measure does not answer all of those questions.

Study participation differs from routine care. Ask how follow-up in a study compares with the service you would actually receive. Evidence should inform your discussion without becoming a promise in a consultation.

Why the 2026 treatment landscape changes the question

The MHRA has authorised Wegovy doses up to 7.2 mg for specified adults with obesity. SURMOUNT-5 did not test that dose. Its result must not be described as a head-to-head finding against every current Wegovy regimen.

Wegovy tablets were also authorised in the UK in June 2026. They were not the semaglutide formulation in SURMOUNT-5. Oral and injectable treatment evidence should not be silently substituted for one another.

These approvals do not establish that Puri Pharmacy supplies every option, that an option is NHS-funded for you or that it is suitable for your circumstances. Ask about the exact currently available pathway rather than assuming approval and access mean the same thing.

A useful comparison for your own consultation

Bring a short list of questions that connects the evidence to your situation:

  • Which options are appropriate for my medical history, and why?
  • Does the trial population resemble my circumstances?
  • Which formulation and dose does the quoted result concern?
  • What side effects would make us review the plan sooner?
  • How will nutrition, symptoms and daily functioning be assessed?
  • What follow-up and costs are involved, including if treatment changes?

If you already take a medicine, bring your actual treatment history. Starting a new treatment and switching after a period of established use are different clinical decisions. A comparison article does not provide an equivalent-dose conversion.

Two people review information on a tablet in a consultation room.
A clear record supports an individual care plan.
Rahul Puri, pharmacist

Ask Rahul

Rahul Puri | Pharmacist

Weight management: evidence, safety and practical next steps

Does the bigger trial percentage identify the best medicine for me?

No. The trial comparison is useful evidence at the doses and in the population studied. Your assessment must also consider suitability, tolerability, other medicines and the support needed to continue safely.

How Puri Pharmacy and Aide Health fit into the decision

Our approach to medical weight-management care combines individual review with Aide Health check-ins, progress recording and health education. That support helps you bring more useful information to the discussion than a single weight reading.

For example, keep a note of the practical issue you want to resolve: persistent symptoms, difficulty with meals or uncertainty about progress. The right question is which plan fits your needs and can be reviewed clearly, not which headline percentage looks most impressive.

Do not combine or switch medicines based on this comparison. Ask the prescriber responsible for your care to explain the decision and any transition instructions.

Frequently asked questions

Did the trial include people with type 2 diabetes?

No. This particular comparison excluded type 2 diabetes, so its numbers should not automatically be presented as expected outcomes for that population.

Does this compare Mounjaro with the Wegovy tablet?

No. The direct trial discussed here used injections. A tablet comparison needs its own evidence and administration guidance.

Can I compare results from two unrelated trials?

You can describe each study with its limitations, but a difference between separate trial averages is not the same as a randomised head-to-head comparison. Populations, follow-up and analysis can differ.

Should I switch because another medicine has a larger study average?

Discuss the reason for considering a change, your current response and your health history. A group average alone is insufficient to choose your treatment.

Key takeaways

  • Name the study population, formulation, doses and duration before quoting results.
  • Average weight loss is useful evidence, not a personal forecast.
  • The cited head-to-head trial did not test Wegovy 7.2 mg or tablets.
  • Choose the next clinical discussion around your health needs and current experience.

Your next step with Puri Pharmacy

Put the evidence in the context of your care

Speak to Puri Pharmacy about your weight-management goals, current treatment and the support available. Any treatment recommendation requires individual assessment.

Discuss your weight-management options

Explore our approach to medical weight management

For routine enquiries. Treatment depends on individual assessment. Urgent symptoms need urgent medical care.

Share:
Stay informed

Get practical health advice and updates on Puri Pharmacy services straight to your inbox.

Weight-management care in Southall, Hillingdon and online

Puri Pharmacy offers face-to-face weight-management consultations at our Southall and Hillingdon clinics. Choose a local appointment to discuss your health, goals and suitable support.

Puri Pharmacy Southall shopfront

Puri Pharmacy Southall

39 Western Road, Southall, UB2 5HE

Call Southall

Southall clinic details and directions
020 8574 6848

Puri Pharmacy Hillingdon shopfront

Puri Pharmacy Hillingdon

165 Ryefield Avenue, Hillingdon, UB10 9DA

Call Hillingdon

Hillingdon clinic details and directions
01895 272571

Online assessment and remote support

You can also start an online assessment and ask about remote consultations and support from elsewhere in the UK. Care is subject to clinical suitability; your clinician will explain whether measurements, examination or another step requires attendance. Assessment does not guarantee treatment.

Explore weight-management care and appointment options.

Start a confidential online assessment.

These are routine care routes. For urgent or worsening symptoms, follow the urgent-care advice in this article rather than waiting for an online assessment or appointment.